Reported Wednesday, Jun 11 - 8:32am EDT (TheFly subscription required to read more.)

TC BioPharm has reported a complete molecular response in a patient with Minimal Residual Disease after innovative gamma delta T cell therapy, marking a significant milestone.

TC BioPharm announces successful completion of Cohort A in the ACHIEVE clinical trial, showcasing promising results for TCB008 in treating AML.

TC BioPharm celebrates a key achievement in its ACHIEVE trial by administering the initial doses to a patient in Cohort B, paving the way for innovative cancer therapies.

TC BioPharm announces intentions to initiate preclinical studies for TCB008, targeting H5N1, aimed at finding innovative treatments for the viral infection.

TC BioPharm announces completion of full-dose regimen in its ACHIEVE Phase 2b trial, with a strong safety profile and promising recruitment figures for 2025.

TC BioPharm provides a quarterly update on the ongoing ACHIEVE clinical trial, revealing positive safety data and plans for dose escalation of TCB008.

TC BioPharm initiates preclinical studies for TCB008, targeting H5N1 bird flu treatment. Company seeks university partnerships to accelerate development amid growing concerns.

TC BioPharm progresses M&A talks targeting NK cell and CAR technologies to expand therapeutic reach into autoimmune diseases and solid tumors, enhancing TCB008 platform capabilities.

TC BioPharm's ACHIEVE trial shows promising safety profile for TCB008 in AML treatment, with multiple patients completing full dosing regimen. Key enrollment milestones reached.

Positive safety data, allowing for exploration of higher TCB008 doses 4 UK-based clinical sites recruiting patients, with a further 2 sites expected in H1 2025 EDINBURGH, Scotland, Dec. 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or…